Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) Return on Sales (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Return on Sales for 11 consecutive years, with 4.28% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 445.0% to 4.28% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.28%, a 69.0% increase, with the full-year FY2025 number at 5.39%, down 256.0% from a year prior.
  • Return on Sales was 4.28% for Q4 2025 at Regen BioPharma, up from 9.64% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.13% in Q3 2021 to a low of 15.21% in Q4 2022.
  • A 5-year average of 3.56% and a median of 2.33% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -1074bps in 2022, then surged 1276bps in 2023.
  • Regen BioPharma's Return on Sales stood at 4.47% in 2021, then tumbled by -240bps to 15.21% in 2022, then surged by 84bps to 2.45% in 2023, then crashed by -256bps to 8.73% in 2024, then surged by 51bps to 4.28% in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Return on Sales are 4.28% (Q4 2025), 9.64% (Q3 2025), and 2.83% (Q2 2025).